Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2024-06-06 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated June 6, 2024, announcing that Theraclion's SONOVEIN® technology was highlighted at medical conferences and published in a scientific journal. It details clinical results (98% success rate), mentions KOL presentations, and provides company background. This type of announcement, focusing on scientific validation, clinical milestones, and general business updates outside of mandatory financial reporting periods (like 10-K or IR), is best classified as a general announcement or press release. Since there is no specific category for 'Scientific/Clinical Update Press Release,' and it is not a formal financial filing (10-K, IR, ER), nor a specific corporate action (DIV, CAP, MANG), the most appropriate fallback category is Regulatory Filings (RNS), which often serves as the catch-all for non-standard, material company news releases.
2024-06-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 6, 2024, from Theraclion, announcing positive clinical results for its SONOVEIN® technology presented at medical conferences and published in a scientific journal (*Phlebology, The Journal of Venous Disease*). It details clinical success rates and KOL presentations. This type of announcement, which disseminates recent business/clinical achievements and scientific validation outside of mandatory periodic financial reports (like 10-K or IR), typically falls under a general press release or regulatory announcement category. Since it is not a formal financial report (10-K, IR, MRQ), a specific management discussion (MDA), or a transcript (CT), and it is not announcing a dividend (DIV) or a capital change (CAP/SHA), the most appropriate classification is a general Regulatory Filing (RNS), which serves as a broad category for significant, non-standardized corporate news releases.
2024-06-06 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release titled 'THERACLION ANNONCE SES RÉSULTATS FINANCIERS 2023'. It provides a summary of financial performance, including a table of income statement items (revenue, operating expenses, net loss) and cash position for the fiscal year 2023. While it contains financial data, it is structured as a corporate announcement (press release) rather than a full statutory annual report (10-K) or a formal interim report (IR). According to the classification guidelines, this type of initial announcement of financial results is classified as an Earnings Release (ER). FY 2023
2024-03-27 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is titled "THERACLION ANNOUNCES 2023 FINANCIAL RESULTS AND CONTINUES ITS ROADMAP" and presents detailed financial tables for the year ended December 31, 2023, including Revenues, Operating result, and Net result. It also discusses operational milestones, capital increases, and R&D progress related to the fiscal year. This content structure—a comprehensive review of annual performance with detailed figures and management commentary—is characteristic of an Annual Report (10-K) or a detailed Earnings Release/Interim Report. Since it covers the full fiscal year (2023) and provides extensive financial detail, it aligns best with the scope of an Annual Report, although it might be an Earnings Release (ER) or Management Discussion & Analysis (MDA) accompanying the 10-K filing. Given the depth of the financial tables and the year-end focus, it is most likely the primary document summarizing the full year's performance, which often precedes or is part of the 10-K filing process. However, in the context of standard regulatory filings, a document that presents the full year's results with detailed financial statements (even summarized here) is often classified as an Earnings Release (ER) if it's the initial public announcement, or an Interim Report (IR) if it were semi-annual. Since it explicitly states '2023 Financial Results' and provides a full year's P&L summary, it functions as the primary financial disclosure for the period. If this were a full 10-K, it would typically reference the SEC filing explicitly. Given the format, it strongly resembles a detailed Earnings Release (ER) or the financial section of a Management Discussion & Analysis (MDA). Since it contains the full set of annual results and management commentary on those results, MDA is a strong candidate, but ER is often used for the initial public release of annual numbers. Comparing ER (initial highlights) vs MDA (detailed explanation): this document contains both highlights and detailed explanations/tables. Since it is a comprehensive review of the full year's results, MDA (Management's detailed explanation of financial results, business trends, and outlook) is a very strong fit, as is ER (initial announcement of periodical financial results). Given the depth, MDA is slightly more appropriate than a simple ER, but ER is also plausible. Let's re-evaluate based on the definitions. It is not a full 10-K. It is more than just highlights (ER). It is a detailed explanation of results and outlook (MDA). It is not a transcript (CT) or a presentation (IP). I will classify it as MDA due to the detailed operational and financial commentary accompanying the results. FY 2023
2024-03-27 English
Inside Information / Information on annual revenues
Earnings Release Classification · 1% confidence The document is titled "THERACLION PURSUES ITS STRATEGY AND ANNOUNCES ITS 2023 REVENUE" and provides detailed financial figures for the year 2023, including turnover, sales breakdowns, and comparisons to 2022. It discusses strategic progress (US market access, China partnership) alongside these financial results. This structure—a comprehensive summary of annual performance, strategic updates, and detailed tables—is characteristic of an Earnings Release (ER) or potentially a section of an Annual Report (10-K). However, given the context of a press release format announcing the results for a specific period (2023 revenue) and the relatively short length (under 5,000 characters), it most closely aligns with an Earnings Release (ER), which provides the initial announcement of key financial highlights for a period. It is not a full 10-K, nor is it a transcript (CT) or a formal audit report (AR). FY 2023
2024-01-29 English
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 1% confidence The document is titled "THERACLION POURSUIT SA STRATÉGIE ET ANNONCE SON CHIFFRE D'AFFAIRES 2023" (THERACLION CONTINUES ITS STRATEGY AND ANNOUNCES ITS 2023 REVENUE). It explicitly states the company's revenue for 2023 (1,822 K€) and provides a detailed breakdown of revenue sources, including system sales, consumables, and license royalties. This content structure—announcing key financial figures for a period (2023) immediately following the period's end (January 29, 2024)—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often before the full, audited report (10-K or IR). It is not a comprehensive Interim Report (IR) as it covers the full year, nor is it a full Annual Report (10-K). It is a summary announcement of financial performance. FY 2023
2024-01-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.